Severe Intrahepatic Cholestasis at 34 Weeks: When the Patient Wants to Wait
A 31-year-old G2P1 at 34 weeks 2 days presents with a 10-day history of intense pruritus, worst on the palms and soles, with no rash. She had a spontaneous preterm birth at 36 weeks in her prior pregnancy and is anxious about delivering early again. Blood pressure is 112/70 mm Hg, urine protein is negative, and fetal growth and amniotic fluid volume are normal. A reactive nonstress test is obtained. Laboratory results show total bile acids 118 micromol/L (reference <10), ALT 145 U/L, AST 110 U/L, bilirubin 0.6 mg/dL, and platelets 210,000/microL. She reports sleeping poorly because of itching but has no jaundice, right upper quadrant pain, or headache. She asks whether she can 'wait until 38 weeks' because she believes the baby needs more time.
1. What is the diagnosis and risk category, and which findings drive your interpretation?
Read the worked answer
The diagnosis is intrahepatic cholestasis of pregnancy (ICP). The key finding is pruritus without a rash plus total bile acids of 118 micromol/L, which is well above the diagnostic threshold of 10 micromol/L; ALT and AST elevation support hepatic involvement. Because bile acids are at least 100 micromol/L, this is severe, highest-risk ICP. That category carries the greatest stillbirth risk and is also associated with preterm labor, meconium-stained fluid, and fetal distress. The normal blood pressure, negative protein, and normal platelets make preeclampsia with severe features unlikely, although ICP and preeclampsia can coexist. Bilirubin is only mildly elevated and there is no jaundice, so acute fatty liver or viral hepatitis is less likely; obtain viral hepatitis serologies and right upper quadrant ultrasound if clinically indicated. The prior preterm birth is relevant to counseling but does not justify delaying delivery in severe ICP.
2. Outline your immediate management, including medications, fetal surveillance, and counseling about delivery timing.
Read the worked answer
Arrange same-day obstetric or maternal-fetal medicine consultation. Start ursodeoxycholic acid 10 to 15 mg/kg/day in divided doses for pruritus; it improves symptoms and may lower bile acids, but it has not been proven to eliminate stillbirth risk. Check PT/INR and consider vitamin K only if fat malabsorption or abnormal coagulation is present. Obtain at least twice-weekly nonstress tests and biophysical profiles while undelivered, and teach daily fetal movement counting with clear return precautions for decreased movement, bleeding, or severe abdominal pain. Give antenatal corticosteroids if delivery is anticipated within 7 days at 34 to 36 6/7 weeks; at 34 weeks 2 days with planned delivery at 36 weeks, time the course with maternal-fetal medicine so it is completed before delivery. Counsel that delivery at 36 0/7 to 36 6/7 weeks is recommended for bile acids at least 100 micromol/L because stillbirth risk rises near term. Explain that the prior preterm birth does not make 38 weeks safer; the current risk is cholestasis-related stillbirth.
3. She declines delivery at 36 weeks. How do you respond, and what is documented?
Read the worked answer
First assess decision-making capacity and explore her fears. Use shared decision-making: state clearly that you recommend delivery at 36 weeks, explain the stillbirth risk with bile acids at least 100 micromol/L, and correct the misconception that waiting always helps the baby. Offer a written plan and a second opinion from maternal-fetal medicine. If she still declines, document informed refusal, her capacity, the risks discussed, and the alternative plan: continued ursodeoxycholic acid, at least twice-weekly fetal surveillance, daily kick counts, and immediate evaluation for decreased fetal movement. Do not abandon her; schedule close follow-up and a clear threshold for induction. Notify the collaborating physician or maternal-fetal medicine and risk management per policy. If fetal testing becomes nonreassuring or she develops severe symptoms, recommend immediate delivery and escalate.